Abstract
We retrospectively analysed neuromuscular toxicity associated with paclitaxel 210 mg m(-2) given by 3-h infusion in 247 patients. The severity correlated significantly with total cumulative dose, but could not be predicted by the pretreatment clinical variables or by pharmacokinetic parameters. The toxicity tended to occur in early treatment cycles.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kunitoh, H., Saijo, N., Furuse, K. et al. Neuromuscular toxicities of paclitaxel 210 mg m-2 by 3-hour infusion. Br J Cancer 77, 1686–1688 (1998). https://doi.org/10.1038/bjc.1998.278
Issue Date:
DOI: https://doi.org/10.1038/bjc.1998.278
This article is cited by
-
Dexamethasone dose-dependently prevents taxane-associated acute pain syndrome in breast cancer treatment
Supportive Care in Cancer (2023)
-
Risk factor analysis for taxane-associated acute pain syndrome under the dexamethasone prophylaxis
Supportive Care in Cancer (2021)
-
Efficacy of additional dexamethasone administration for the attenuation of paclitaxel-associated acute pain syndrome
Supportive Care in Cancer (2020)
